ViiV Healthcare Announces Phase III Study Meets Primary Endpoint\, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato in Virally Suppressed Patients Switching From a TAF-containing\, 3-drug Regimen